Brainstorm Cell Therapeutics Inc (BCLI)

04:01 AM

What drives Brainstorm Cell Therapeutics Inc. stock priceHigh-margin investment plays - Autocar Professional

04:01 AM

Jul 22, 2025

What analysts say about Brainstorm Cell Therapeutics Inc. stockFastest return on investment - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Is Brainstorm Cell Therapeutics Inc. a good long term investmentOutperformance with explosive growth - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Brainstorm Cell Therapeutics Inc. Stock Analysis and ForecastFree Stock Market Knowledge Sharing - jammulinksnews.com

Jul 22, 2025

Jul 19, 2025

BrainStorm Cell Therapeutics to move from Nasdaq to OTCQB after delisting; shares down - MSN

Jul 19, 2025

Jul 18, 2025

INVESTOR ALERT: Levi & Korsinsky Reminds Brainstorm Cell Therapeutics Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024BCLI - ACCESS Newswire

Jul 18, 2025

Jul 18, 2025

BrainStorm Cell Therapeutics Crashes After Hours On Nasdaq Delisting Notice; Retail Sees 'Buy Time' - Stocktwits

Jul 18, 2025

Jul 18, 2025

Brainstorm Cell Therapeutics Crashes 42% After Voluntary Nasdaq Delisting Announcement - inkl

Jul 18, 2025

Jul 17, 2025

Brainstorm Cell Therapeutics Faces Nasdaq Delisting Notice - TipRanks

Jul 17, 2025

Jul 17, 2025

Brainstorm Cell Therapeutics to Delist From Nasdaq - MarketScreener

Jul 17, 2025

Jul 17, 2025

BrainStorm Cell Therapeutics shares fall 51.20% after-hours after Nasdaq delisting notification. - AInvest

Jul 17, 2025

Jul 17, 2025

BrainStorm Cell Therapeutics stock delisted from Nasdaq, trades on OTCQB - AInvest

Jul 17, 2025

Jul 17, 2025

BrainStorm Cell Therapeutics to delist from Nasdaq, move to OTCQB By Investing.com - Investing.com India

Jul 17, 2025

Jul 17, 2025

BrainStorm Cell Therapeutics to delist from Nasdaq, move to OTCQB - Investing.com

Jul 17, 2025

Jul 17, 2025

BrainStorm Cell Faces Nasdaq Exit: What the OTCQB Switch Means for Investors and NurOwn Program - Stock Titan

Jul 17, 2025

Jul 17, 2025

BrainStorm Receives 3 Million NIS Grant from Israel's Office of the Chief Scientist - AOL.com

Jul 17, 2025

Jul 15, 2025

Why Brainstorm Cell Therapeutics Inc. stock attracts strong analyst attentionFree Deep Market Trend Analysis - Newser

Jul 15, 2025

Jul 15, 2025

What makes Brainstorm Cell Therapeutics Inc. stock price move sharplyFree Stock Trading Community - Newser

Jul 15, 2025

Jul 15, 2025

How Brainstorm Cell Therapeutics Inc. stock performs during market volatilityFree Access to Community with 300% Return - Newser

Jul 15, 2025

Jul 09, 2025

FDA to review citizen petition on BrainStorm’s ALS therapy NurOwn By Investing.com - Investing.com South Africa

Jul 09, 2025

Jul 08, 2025

ALS Community Petitions FDA To Reconsider BrainStorm’s NurOwn, Pointing to Recent Survival Data - BioSpace

Jul 08, 2025

Jul 08, 2025

BTCS, BrainStorm Cell, Moderna - TradingView

Jul 08, 2025

Jul 08, 2025

FDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment Effectiveness - The Malaysian Reserve

Jul 08, 2025

Jul 08, 2025

BrainStorm Cell Therapeutics: A Rare Disease Breakthrough on the Brink of Regulatory Approval - AInvest

Jul 08, 2025

Jul 08, 2025

NurOwn's Regulatory Crossroads: Why BrainStorm Cell Therapeutics (BCLI) Could Be Poised for a Turnaround - AInvest

Jul 08, 2025

Jul 08, 2025

FDA to review citizen petition on BrainStorm’s ALS therapy NurOwn - Investing.com

Jul 08, 2025

Jul 07, 2025

BCLI: Citizen's Petition Filed Requesting the FDA Approve NurOwn - Smartkarma

Jul 07, 2025

Jul 07, 2025

ALS Community Files Citizens’ Petition asking FDA to Approve NurOwn Stem Cell Therapy - Asbury Park Press

Jul 07, 2025

Jul 01, 2025

5 Best Stem Cell Companies to Invest In (July 2025) - Securities.io

Jul 01, 2025

Jun 30, 2025

SHAREHOLDER ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Jun 30, 2025

Jun 27, 2025

Press Release Service: Gene and Cell Therapies Targeting CNS Disorders Market Research 2025-2035 | Novartis, BrainStorm Cell Therapeutics, Neuroplast, Rapa Therapeutics, and Longeveron Driving InnovationsResearchAndMarkets.com - CRISPR Medicine News

Jun 27, 2025

Jun 25, 2025

NurOwn's Next Act: BrainStorm Cell Therapeutics' Share Resale and the ALS Trial Gamble - AInvest

Jun 25, 2025

Jun 20, 2025

9 of 10 NurOwn-treated ALS patients surpass five-year survival - ALS News Today

Jun 20, 2025

Jun 17, 2025

Autologous Cell Therapy Market Size, Global Trends And Forecast to 2033 - Straits Research

Jun 17, 2025

Jun 16, 2025

Brainstorm Cell's NurOwn Study Data Shows 90% Survival Rate In ALS Patients, Stock Up In Pre-Market - Nasdaq

Jun 16, 2025

Jun 16, 2025

Encouraging Survival Data Revealed for BrainStorm's NurOwn in ALS Study (BCLI) | BCLI Stock News - GuruFocus

Jun 16, 2025

Jun 16, 2025

BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn® - PR Newswire

Jun 16, 2025

Jun 16, 2025

BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn® – Company AnnouncementFT.com - Financial Times

Jun 16, 2025

Jun 14, 2025

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Rating Increased to Sell at Wall Street Zen - Defense World

Jun 14, 2025

Jun 10, 2025

Corestemchemon preps US BLA filing for stem cell ALS therapy - BioWorld MedTech

Jun 10, 2025

Jun 06, 2025

Brainstorm taps Minaris to produce NurOwn for Phase 3b trial - ALS News Today

Jun 06, 2025